Retrotransposons: A New Frontier in In Vivo Genome Engineering
Genome engineering has transformed cell therapy, but clinical implementation remains largely confined to ex vivo workflows followed by adoptive cell transfer. These approaches require costly manufacturing, often rely on viral vectors, and carry risks associated with unwanted genomic alterations. Recent advances in lipi...
Philippe Kieffer-Kwon, Meghan T. Harris, Daniel R. Getts et al.
· Pharmaceutics · 0 citations